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In this study, we describe the key transcripts and machine learning models developed 25 for classifying the early and late stage samples of Papillary Thyroid Cancer (PTC), 26 using transcripts' expression data from The Cancer Genome Atlas (TCGA). First, we 27 rank all the transcripts on the basis of area under receiver operating characteristic curve, Thyroid Carcinoma) and Follicular Thyroid Carcinoma (FTC) are known as 58
Other datasets 149
In addition to stage classification, we also developed model for discriminating cancer 150 patients and normal tissues. This dataset comprises of 500 cancer samples and 58 151 normal samples. Similarly, we also developed models for predicting normal, early and 152 late stage. The dataset for multiclass classification comprises of 58 normal, 333 early 153 stage and 167 late stage samples. These datasets were further subdivided into training 154 and independent validation dataset, where training dataset contained 80% samples and 155 independent validation dataset contained 20% samples. 156
Data processing 157
The FPKM values were log2 transformed after addition of 1.0 as a constant number to 158 each of the value. After that, we removed features with low variance (less than 0.25) by 159 employing caret package in R, followed by z-score normalization of data. The equations 160
(1) and (2) were used for log transformation and normalization of data, respectively. 161 = 2 ( + 1) (1) 162
In equation (2), Zscore is the normalized scaled and centered score, x is the log-164 transformed transcript expression, ̅ is the mean of transcript's expression in the 165 training dataset, and s is the standard deviation of a transcript in the training dataset. 166
The log2 transformed independent validation data is z normalized by taking mean and 167 standard deviation of training features. 168
Features filtering using threshold-based models 169
In this study, we employed a simple expression threshold based approach similar to our 170 previous study (Bhalla et al., 2017) to develop threshold-based models. This method is 171 based on the fact that few transcripts are differentially expressed in early stage as 172 compared to the late stage. In this approach, for every transcript, we designated athreshold, which determines whether a sample is in the early or late stage of the cancer. 174
The threshold is selected by iterating from the minimum to maximum expression of that 175 transcript across all the patients. The threshold which gives maximum AUROC of 176 classification between early and late stage sample is reported. If the mean expression of 177 transcript is greater in early stage than late stage and for a given sample, its log2 FPKM 178 value is higher than the given threshold, then we assign that sample as early otherwise as 179 the late stage sample. Whereas, if the transcript's average log2 FPKM value is greater in 180 late stage as compared to the early stage and for a given sample, if its log2 FPKM is 181 greater than the threshold, then we assign that sample as the late otherwise as the early 182 stage sample. Using similar method AUROC is calculated for cancer vs. normal samples. 183
Feature selection 184
To further improve the classification accuracy and develop a multiple gene 185 classification models, we used state-of-the-art techniques to select relevant features. 186 
statistics. 194
Thirdly, for the model which performed best in comparison to other models, we applied 195 two more feature selection methods. One is wrapper approach for feature selection and 196 other is SVC with L1 penalty (Baraniuk, 2007) . In wrapper based approach, human The models developed using 80% data on the best parameters obtained using grid 222 search were used to evaluate independent 20% dataset which was not used for feature 223 selection and training. 224
External validation 225
Further to validate the models on the external validation dataset, first the TCGA data 226 was log2 normalized. Then, the GSE48953 expression data was quantile normalized 227 with reference to TCGA training dataset (target set) using FSQN package (Franks et 228 al., 2018) . 229
Performance measures
230
In present study, performance of different models was measured by employing 231 threshold-dependent and threshold-independent parameters. In case of threshold-232 dependent parameters, sensitivity (Sen), specificity (Spc), overall accuracy (Acc (%)) 233
and Matthews correlation coefficient (MCC) was calculated by using equations (3), (4), 234 We also calculated a threshold-independent parameter called AUROC, which is 244 computed from receiver operating characteristic (ROC) plot in this study. The ROC curve 245 is produced by plotting true positive rate against the false positive rate at different 246 thresholds. Lastly, we calculated the area under ROC curve to compute a single parameter 247 from this curve called AUROC in the current study. We used this AUROC value for 248 optimizing and measuring the performance of our models. 249
In addition, to ascertain the reliability of prediction, we calculated PPV (Positive 250
Predictive Value) and NPV (Negative Predictive Value) at various thresholds using 251 probability score obtained by employing SVM. 252
253
Multiclass classification 254
Multiclass classification is implemented using WEKA algorithm using 255 WEKA.classifiers.meta.MultiClassClassifier with random forest as classifier. This 256 method is capable for handling multi-class datasets with 2-class classifiers. This classifier 257 also applies error adjusting output codes for improved accuracy. not sufficient for developing prediction models. 325
Protein coding transcripts 326
As from the previous results, it is evident that protein coding transcripts were major 327 type of transcripts in THCA-EL-AUROC signature, therefore in this analysis we 328 Table 1 ) 335 using 37 features obtained using SVM. There was marginal increase in the performance 336 accuracy but the number of features was reduced to reasonable extent as compared to 337 THCA-EL-AUROC. The performance using other algorithms like random forest, 338 Naïve Bayes, SMO and J48 is also shown in Table 1 . 339
We performed interaction analysis in STRING database (Szklarczyk et al., 2015 ) 340 Figure S4) with THCA-EL-PC transcripts. On adding not more thanHIST1H2BJ, the transcript present in our signature forms a cluster and this cluster is 343 enriched in nucleosome cellular component. This cluster has also shown to be related 344 with progression of prostate cancer (Xu et al., 2017) in literature. Another cluster of 345 three genes is enriched in dihydrolipoyl dehydrogenase complex FDR <0.01), out 346 which DBT is present in our original signature. In addition, one more cluster of three 347 genes is a part of checkpoint clamp complex out of which RAD1 is present in original 348 signature and is involved in DNA damage response (Hwang et al., 2015) . 349
In addition, the top 100 features (Supplementary Table S5 Table S8) . 372
Protein coding and noncoding transcripts 373
To ascertain the importance of other non-coding transcripts along with protein coding 374 transcripts, all the 60,483 transcripts were used to select features and develop model on 375 selected features. These 78 transcripts (THCA-EL-All-WEKA) were selected using 376 FCBF-WEKA based feature selection algorithm. The best performance on THCA-EL-377
All-WEKA panel is obtained using SVM with 78.89% accuracy with 0.86 AUROC on 378 training data and 74.51% accuracy and 0.73 AUROC on independent validation dataset 379 (Supplementary Table S9 Table S10) . 382
The feature selection through F_ANOVA based method with top 100 features 383 (Supplementary Table S11 ) attained accuracy of 71.86% with AUROC score of 0.72 384 on training data and accuracy of independent validation data of 61.76% with AUROC 385 score of 0.68 (THCA-EL-All-F, Supplementary Table S12) . 386
Additionally, the top 100 features selected using F_ANOVA were further subjected to 387 the second stage of feature selection. In this stage, a wrapper based approach combining 388 human opinion dynamics optimizer and SVM has been employed (see Methods for 389 details). The number of features were reduced to 27 (Supplementary Table S13 , THCA-390 accuracy of 72% and AUROC of 0.73 on independent validation set (Supplementary 392 Table S14 ). 393
As the above three feature selection methods and prediction models gave maximum 394 performance using both protein coding and non-coding transcripts, as compared to 395 protein coding and cancer hallmark protein coding transcripts, we employed another 396 feature selection method which selected features using SVC with L1 penalty (see 397
Methods) which resulted in 36 transcripts. This method gave almost similar accuracy 398 but increased the AUROC from 0.73 to 0.75 (THCA-EL-SVC-L1, Table 2 ) on 399 independent validation data. This model performed best out of all the models developed 400 to discriminate early and late stage samples in terms of number of features and AUROC 401 on independent validation dataset. 402
Further, to ascertain its capabilities, we calculated PPV and NPV on various thresholds 403 of SVM probability score (Table 3) . On training data, at the SVM score, greater than 404 0.9, 161 early stage samples are correctly predicted out of total 170 samples predicted 405 as early stage samples (PPV=94.71%). In case of late stage samples, 60 out of 64 late 406 stage predicted samples are correct (NPV=93.75%). In case of independent validation 407 data, the PPV is 85.71% and the NPV is 66.67% (Table 3 ). This shows that at SVM 408 score of 0.9, there is high probability of correct positive (early stage) and negative (late 409 stage) prediction. At threshold of 0.7, at which we presented other performance 410 measures in Table 2 , the PPV for training data is 93.03% and NPV is 94.51% whereas 411 in case of independent validation the PPV is 83.87% and NPV is 63.64% (Table 3) . 412
We also applied various other state-of-the-art machine learning methods on THCA-EL-413 SVC-L1, but SVM performed best out of all (Supplementary Table S15 (Table 4) . 445
An interesting observation was seen when these 211 transcripts were analyzed in 446 STRING. As we added 5 indirect iterations to the network, many of the protein coding 447 transcripts in our signature were interacting with PCNA (Supplementary Figure S5) . 448 PCNA has been associated with fatal outcomes (Basolo et al., 1993) . The genes in our 449 signature directly interacting with PCNA points out to their importance in acting as 450 stage specific biomarkers. 451
Correlation Disturbance in Early and late stages of cancer 452
To further elucidate the expression of various transcripts in early versus late stage, the 453 Table S18) were segregated for subsequent analysis based on the 458 assumption that this large change or disturbance in correlation is due to diseased 459 condition. These were the gene pairs whose correlation has been disturbed drastically 460 in early stage as compared to late stage and vice versa. From this analysis, we obtained 461 two types of transcripts i.e. one which had low correlation in early stage patients but 462 high correlation in late stage patients (L_pairs) and others had high correlation in earlythan 0.6. There were total 453 pairs which had correlation of 0.60 or higher in early 467 samples and their correlation difference between early and late samples is at least 0.7. (Table 5) . 2011). We also selected features using WEKA and achieved similar performance as of 559
features based models (Data not shown). 560
Web Server Implementation 561
We established a web server, CancerTSP (Thyroid cancer stage prediction), that 562 implements models established in the present study for investigation and estimation of 563 cancer stage from the transcripts' expression data. CancerTSP consists of three key 564 modules; first for prediction whether sample is cancerous or normal, second is forpredicting whether it is in early or late stage cancer, and third is for the analysis of 566 transcripts' expression data. 567
Prediction module allows the users to predict whether the sample is cancerous or not 568 and also predicts the stage of the cancer using FPKM values. The user needs to provide 569 transcript expression (FPKM values) of potential biomarker genes for every patient. 570
The number of patients corresponds to the number of columns in a file. The output 571 includes a list for patient and corresponding predicting stage of cancer (early or late 572 stage) along with the prediction score (Probability value). The user can use THCA-CN-573 F for predicting cancer vs normal, THCA-NEL-M for normal vs early vs late, and 574
THCA-All-SVC-L1, THCA-EL-All-WEKA and THCA-EL-PC for predicting early vs 575 late stage. 576
Another module consists of analysis module which is helpful in evaluating the role of 577 each transcript in discrimination of early stage from the late stage. This module gives 578 p-value (calculated using Wilcoxon rank test) for each transcript that signifies whether 579 the transcript's expression varies in the early and late stage significantly. It also gives 580 expression threshold and classifying AUROC of each transcript along with average 581 expression of that gene in the early and late stage of cancer. This web server is available 582 from URL "http://webs.iiitd.edu.in/raghava/cancertsp/" for public use. 583
Discussion and conclusion
584
The current study is an attempt to explore the reliable expression-based markers capable 585 of segregating early stage patients from late stage patients. The FNA allows the 586 diagnosis of nature of thyroid nodules in the majority of cases. However, despite the 587 benefits of FNA for diagnosing papillary, medullary, and anaplastic thyroid cancer, it 588
is not helpful in determining whether the thyroid tumors are benign or malignant. Incancer (Grogan et al., 2010) . With the advent of genomics technology, publicly 591 available cancer patient's expression data from resources like TCGA has expedited the 592 search for expression-based molecular markers, capable of reliable diagnosis in clinical 593
settings. 594
In this work, we made an attempt to understand how well (prediction power in terms 595 of AUROC) the gene expression predicts the stage of the THCA tumor samples. Figure1: Flowchart representing the overall flow of study, including the types of feature 1058 spaces explored for development of machine learning models.
